In this study, EB-WE was shown to enhance AMPK activity in the liver and muscle tissues in the MASLD mouse model, suggesting that AMPK activation is a key factor in its anti-MASLD effect (Figure 5, Figure 6 and Figure 7). This evidence concerns the gene PRKAA2 and metabolic dysfunction-associated steatotic liver disease.